Christine Chung

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 33:1804-8. 2011
  2. doi Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Oncologist 13:725-32. 2008
  3. pmc Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    C H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
    Ann Oncol 21:864-70. 2010
  4. doi Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307 USA
    Clin Cancer Res 15:6758-62. 2009
  5. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
  6. pmc Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
  7. pmc Gene expression profiles as markers of aggressive disease-EGFR as a factor
    Christine H Chung
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S102-5. 2007
  8. ncbi Genomics and proteomics: emerging technologies in clinical cancer research
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Crit Rev Oncol Hematol 61:1-25. 2007
  9. ncbi Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 24:4170-6. 2006
  10. ncbi Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Res 66:8210-8. 2006

Detail Information

Publications26

  1. pmc Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 33:1804-8. 2011
    ..Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R])...
  2. doi Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Oncologist 13:725-32. 2008
    ..Considering the heterogeneity of infusion reactions, clinicians need to recognize the underlying nature of these events in order to identify patients at risk as well as provide optimal prophylactic measures and management of symptoms...
  3. pmc Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    C H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
    Ann Oncol 21:864-70. 2010
    ..The combination of bortezomib, an NF-kappaB inhibitor by inhibition of proteasomes, plus docetaxel was assessed for efficacy and toxicity...
  4. doi Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307 USA
    Clin Cancer Res 15:6758-62. 2009
    ..Further understanding of carcinogenesis and clinical behavior of HPV-positive cancers will improve disease prevention, patient care, and surveillance strategies for HNSCC patients...
  5. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  6. pmc Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
    ..In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG...
  7. pmc Gene expression profiles as markers of aggressive disease-EGFR as a factor
    Christine H Chung
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S102-5. 2007
  8. ncbi Genomics and proteomics: emerging technologies in clinical cancer research
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Crit Rev Oncol Hematol 61:1-25. 2007
    ..We will present a framework for future directions of these technologies and how we believe they should be applied in clinical studies...
  9. ncbi Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 24:4170-6. 2006
    ..A better understanding of the EGFR pathway may improve the use of EGFR inhibitors in HNSCC...
  10. ncbi Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Res 66:8210-8. 2006
    ..The 75-gene list can be used as a prognostic biomarker of recurrence, and our data suggest that the molecular determinants of EMT and NF-kappaB activation can be targeted as the novel therapy in the identified high-risk patients...
  11. ncbi Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbuilt Ingram Cancer Center, Vanderbuilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 5:489-500. 2004
    ..This work represents an important step toward the identification of clinically significant biomarkers for HNSCC...
  12. ncbi Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma
    Robbert J C Slebos
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 12:701-9. 2006
    ..These properties may be exploited as a target of novel therapeutic agents in HNSCC treatment...
  13. ncbi Clinical applications of genomics in head and neck cancer
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2559, USA
    Head Neck 28:360-8. 2006
    ..In this review, we will discuss advances, limitations and future directions of genomics as it applies to HNSCC...
  14. pmc Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer
    Brian Bierie
    Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
    J Clin Invest 119:1571-82. 2009
    ..Together, the results suggest that assessment of TGF-beta signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer...
  15. ncbi Molecular portraits and the family tree of cancer
    Christine H Chung
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, North Carolina 27599, USA
    Nat Genet 32:533-40. 2002
    ..The early results are painting a detailed portrait of cancer that illustrates the individuality of each tumor and allows familial relationships to be recognized through the identification of cell types sharing common expression patterns...
  16. pmc Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab
    Shizhen Emily Wang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 28:5605-20. 2008
    ....
  17. doi Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
    ..Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC...
  18. pmc Update on molecular diagnostic tests in head and neck cancer
    Kevin T Palka
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Semin Oncol 35:198-210. 2008
    ....
  19. doi Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation
    Barbara A Murphy
    Department of Medicine, Vanderbilt University Medical Center, USA
    Head Neck 32:26-37. 2010
    ....
  20. doi Human papillomavirus in early laryngeal carcinoma
    Jessica L Baumann
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6350, USA
    Laryngoscope 119:1531-7. 2009
    ..To examine the role of HPV status in the etiology, prognosis, and treatment of head and neck squamous cell carcinoma in early larynx malignancies...
  21. ncbi Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee, USA
    Oncology (Williston Park) 23:14-7. 2009
    ..The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed...
  22. doi Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
    ....
  23. pmc A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009
    ....
  24. pmc Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA
    N Engl J Med 358:1109-17. 2008
    ..A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States...
  25. pmc Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling
    Ming Li
    Department of Biostatistics, Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 8575, USA
    J Proteome Res 9:4295-305. 2010
    ....
  26. doi Evolution of clinical trials in head and neck cancer
    Eddy S Yang
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    Crit Rev Oncol Hematol 71:29-42. 2009
    ..Emerging new technologies such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) will also be reviewed. Functional assessments and quality of life issues will be addressed...

Research Grants3

  1. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2007
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  2. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2009
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..